New pill design aims to smooth out Parkinson's drug levels
NCT ID NCT05471609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new oral version of the Parkinson's drug levodopa/carbidopa designed to release the medication slowly over time. Six healthy volunteers took the drug to see if it could keep steady levels in the blood. The goal is to reduce the 'on-off' motor fluctuations that many Parkinson's patients experience with standard pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- levodopa/carbidopa
- What this could lead to
- If successful, this formulation could help Parkinson's patients maintain more stable drug levels, potentially reducing motor fluctuations.
- What could go wrong
- This is a very early, small study in only 6 healthy people, not Parkinson's patients. It only measures drug levels, not actual symptom control, so real-world benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults